IDXG — Interpace Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $2.88m
- $5.70m
- $46.93m
- 51
- 100
- 23
- 59
Annual cashflow statement for Interpace Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.5 | -14.9 | -22 | 0.802 | 6.7 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 1.71 | 1.63 | 14.8 | 1.47 | 0.872 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 5.23 | -0.819 | -3.05 | -0.083 | -3.68 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -14 | -8.72 | -7.69 | 3.79 | 4.65 |
| Capital Expenditures | -1.57 | -0.354 | -0.322 | -0.47 | -0.876 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 0.039 | 6.53 | 0.383 | 0 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -1.57 | -0.315 | 6.21 | -0.087 | -0.876 |
| Financing Cash Flow Items | 0 | -8.36 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 16.6 | 8.98 | 3 | -5.03 | -5.81 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.05 | -0.058 | 1.51 | -1.33 | -2.04 |